MedPath

Monitoring Strategies for the Detection of Atrial Fibrillation in Patients with Cryptogenic Stroke

Not Applicable
Terminated
Conditions
Stroke
Atrial Fibrillation
Registration Number
NCT04644679
Lead Sponsor
Hospital Italiano de Buenos Aires
Brief Summary

Randomized clinical trial comparing two monitoring strategies, the use of a 48-hour Holter (routine care branch) and an event recorder for 7 days (intervention branch).

Patients admitted for cryptogenic stroke will be included. Enrollment and randomization of patients will be carried out during the index case hospitalization, while follow-up will be done on an outpatient basis until day 7.

Detailed Description

Once the diagnose of cryptogenic stroke have been carried out, informed consent will be taken and participants will be randomized to 48-hour monitoring arm or 7-day monitoring arm, followed by discharge from hospital.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
49
Inclusion Criteria
  • All patients who have studies that classify stroke or TIA as cryptogenic and who can carry out monitoring for 48 hours or 7 days will be included.
  • Age ≥ 18 years

Exclusion criteria

  • History of atrial fibrillation (or atrial flutter) documented.
  • Patients who already have an event recorder in place, permanent pacemaker, or implantable cardioverter-defibrillator
  • Evidence of lacunar infarction.
  • Hemorrhagic stroke
  • Patient for palliative care
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Atrial fibrillation7 days

Detection of one episode of atrial fibrillation or atrial flutter \>30 seconds up to 7 days

Secondary Outcome Measures
NameTimeMethod
Supraventricular arrhythmia7 days

Count of beats per day of non-sustained irregular atrial tachyarrhythmia or supraventricular extrasystoles up to 7 days

Trial Locations

Locations (1)

Hospital Italiano de Buenos Aires

🇦🇷

Buenos Aires, C.a.b.a, Argentina

Hospital Italiano de Buenos Aires
🇦🇷Buenos Aires, C.a.b.a, Argentina

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.